Tricida to Present at the 39th Annual J.P. Morgan Healthcare Conference
Get Alerts TCDA Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 11:50 am PT / 2:50 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives.
A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit www.Tricida.com.
Contact: Jackie Cossmon, IRCTricida, Inc.Senior Vice President of Investor Relations and Communications[email protected]
Source: Tricida, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- For Fifth Consecutive Year, ISC Earns the Globe and Mail’s 2024 Women Lead Here Benchmark for Executive Gender Diversity
- NaturEra Debuts Sugar Crush, the Ultimate Blood Sugar Management Supplement Duo with Innovative Liquid Formula
- Stampli's accounts payable platform is recognized as category leader across Gartner Digital Markets brands
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
JPMorgan, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!